Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC7037 | SB 218795 |
| Potent, selective and competitive non-peptide NK3 receptor antagonist (Ki = 13 nM at hNK3). Displays 90-fold and 7000-fold selectivity over hNK2 and hNK1 receptors respectively. Active in vivo, inhibiting agonist-induced pupillary constriction. | |
| BCC7038 | Cromakalim |
| Prototypical Kir6 (KATP) channel opener. Relaxes rabbit isolated portal vein with an IC50 value of 21 nM. Potent, orally active and hypotensive in vivo. | |
| BCC7039 | Levcromakalim |
| Active enantiomer of the prototypical Kir6 (KATP) channel opener cromakalim. Hypotensive and airways relaxant. IC50 = 490 nM in guinea pig trachea. | |
| BCC7040 | SB 221284 |
| Potent, selective 5-HT2C/2B receptor antagonist. pKi values are 6.4, 7.9 and 8.6 for 5-HT2A, 2B and 2C receptors respectively. Centrally active upon systemic administration in vivo. | |
| BCC7041 | L-152,804 |
| Potent, selective non-peptide neuropeptide Y Y5 receptor antagonist (Ki = 26 nM for hY5). Displays > 300-fold selectivity over hY1, hY2, and hY4 receptors. Causes weight loss in diet-induced obese mice by modulating food intake and energy expenditure. Centrally active upon oral administration in vivo. | |
| BCC7042 | McN-A 343 |
| Selective muscarinic M1 receptor agonist. Selectivity for M1 over other muscarinic receptor types appears to arise from a high efficacy at M1 receptors. | |
| BCC7045 | (RS)-3,4-DCPG |
| Systemically active anticonvulsant that is 30-100-fold more potent in vivo than the separate enantiomers (S)-3,4-DCPG or (R)-3,4,-DCPG. | |
| BCC7046 | (R)-3,4-DCPG |
| AMPA receptor antagonist with weak activity at NMDA receptors and little activity at kainate receptors. (RS)-3,4-DCPG and (S)-3,4-DCPG also available. | |
